At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 195 enrolled

Drug / intervention

CP- 690 550 +4 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00787202

NCT00787202Phase 2Completed

Compare CT.gov

A Randomized, Placebo Controlled, Double Blind, Parallel Group Multi-Center Study In Order To Investigate Safety And Efficacy Of CP- 690 550 In Subjects With Moderate To Severe Ulcerative Colitis.

Pfizer·interventional·Posted Nov 7, 2008·Updated Apr 16, 2013

In Brief

A Phase 2 clinical trial evaluating CP- 690 550 and placebo for Ulcerative Colitis. Completed, enrolled 195 participants across 59 sites in 17 countries.

Detailed Summary

The hypothesis of the study is that at least one dose of CP 690 550 is superior to placebo (inactive drug) in inducing remission in patients with moderate to severe ulcerative colitis.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsUlcerative Colitis

CountriesBelgium, Brazil, Chile, Czechia, Denmark, France, Hungary, Israel, Italy, Mexico, Netherlands, Poland, Slovakia, South Africa, Spain, Sweden, United Kingdom

Collaborators--

Timeline

Phase 2CompletedFinished

200920102011201220132014201520162017201820192020202120222023202420252026

First PostedNov 2008

Enrollment StartDec 2008

Primary CompletionSep 2010

TodayJul 2026

First PostedNov 7, 2008

Enrollment StartDec 1, 2008

Primary CompletionSep 1, 2010

TodayJul 2, 2026

Enrollment to primary: 1.8 yearsPosted 17.7 years ago